Obseva

nature meets nurture

Focused on unmet needs in women's reproductive health

July 2021

Disclaimer

Matters discussed in this presentation may constitute forward-looking statements. The forward-looking statements contained in this presentation reflect our views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause our actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from our expectations include our plans to develop and potentially commercialize our product candidates; our planned clinical trials and preclinical studies for our product candidates; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; the extent of clinical trials potentially required for our product candidates; the clinical utility and market acceptance of our product candidates; our plans and development of any new indications for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position; and our ability to identify and in-license additional product candidates. For further information regarding these risks, uncertainties and other factors that could cause our actual results to differ from our expectations, you should read the risk factors set forth in our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the SEC on March 5, 2021, and our other filings we make with the Securities and Exchange Commission from time to time.

We expressly disclaim any obligation to update or revise the information herein, including the forward-looking statements, except as required by law. Please also note that this presentation does not constitute an offer to sell or a solicitation of an offer to buy any securities.

This presentation concerns products that are under clinical investigation and which have not yet been approved for marketing by the US Food and Drug Administration. It is currently limited by federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

About ObsEva

ObsEva (NASDAQ: OBSV and SIX: OBSN) is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor.

- Founded in 2012
- Headquarters: Geneva, Switzerland
- Employees: 47 total EU and US
- Listings: NASDAQ (OBSV) and SIX (OBSN)
- Collaborations with Kissei, Yuyuan Bioscience, Merck Serono

Seasoned leadership team

Brian O'Callaghan
Chief Executive Officer

Petra Pharma
Novartis
Pfizer
Sangart
Merck Serono
Covance

Elizabeth Garner MD, MPH
Chief Medical Officer

Agile Therapeutics
Merck
Abbott
myriad — When Decisions Matter

David Renas
Chief Financial Officer

Petra Pharma
Sangart
DLA Piper
Deloitte.
Adkins Black LLP

Fabien de Ladonchamps
Chief Administrative Officer

addex Therapeutics

Jean-Pierre Gotteland, PhD
Chief Scientific Officer

Pierre Fabre
serono — biotech & beyond
preglem — reproductive medicine

Clive Bertram
Chief Commercial Officer

Petra Pharma
Sangart
Chiron
Lilly
Pharmion

Board of Directors

Frank Verwiel, MD
Chairperson

Ernest Loumaye, MD, PhD

Brian O'Callaghan

Annette Clancy, BSc (Hons)

Anne VanLent

Ed Mathers

Catarina Edfjäll PhD

Jacky Vonderscher, PhD

Obseva

Investor highlights

1. Pursuing large indications for conditions that compromise **women's reproductive health and beyond**
2. Yselty® has potential **best in class efficacy, favorable tolerability, and unique flexible dosing options**
3. Ebopiprant is the only known product in development for preterm labor and has **positive Phase 2a data**
4. Business model built on strong **global partnerships and collaborations**
5. Seasoned **leadership team** with a track record for success

Product overview

YSELTY® (LINZAGOLIX)

Potential to relieve symptoms of heavy menstrual bleeding due to uterine fibroids and pain associated with endometriosis

EBOPIPRANT (OBE022)

Potential to delay preterm birth to improve newborn health and reduce medical costs

NOLASIBAN

Potential to improve live birth rate following IVF & embryo transfer

Multiple development programs drive value

	Phase 1	Phase 2	Phase 3	Next Milestones
YSELTY® (LINZAGOLIX) Oral GnRH receptor antagonist	Uterine Fibroids – Ph3 PRIMROSE 2 (EU & US)			NDA submission (Q3:21) MAA for uterine fibroids expected recommendation (Q4:21)
	Uterine Fibroids – Ph3 PRIMROSE 1 (US)			
	Endometriosis – Ph3 EDELWEISS 3 (EU & US)			EDELWEISS 3: Completed enrollment with primary endpoint readout expected (Q4:21)
EBOPIPRANT Oral $PGF_{2\alpha}$ receptor antagonist	Preterm Labor – Ph2b (EU & Asia)			Initiation of Phase 2b dose ranging study (Q4:21)
NOLASIBAN Oral oxytocin receptor antagonist	IVF – Ph1/2 (China)			In development, partnership with Yuyuan BioScience Technology (PRC)

Obseva
nature meets nurture

yselty®
linzagolix

DESIGNED TO TREAT MORE WOMEN SUFFERING FROM UTERINE FIBROIDS

Yselty®, our proposed trade name for linzagolix, is conditionally acceptable for the FDA. Linzagolix has not been approved by FDA for any indication for use. Linzagolix is an investigational drug.

Uterine fibroids

A significant unmet need translating into a multibillion market

$34B/yr

total US costs from direct costs, lost workdays and complications

9 million

women in the US affected by fibroids

70%+

of women have fibroids by age 50

Quality of Life

premenopausal women may experience heavy menstrual bleeding, anemia, bloating, infertility, pain and swelling

600,000

hysterectomies are performed annually in the US

300,000

are because of uterine fibroids

>4 million

women in the US are treated annually for fibroids

Obseva

Cardozo et al., Am J Obstet Gynecol 2012; Stewart et al. NEJM, 2015; Flynn et al., Am J Obstet Gynecol 2006; Truven Health, Fibroid Foundation website; Epidemiology of women's health, Jones & Bartlett Learning, Ruby T. Senie, 2014

GnRH antagonist mechanism of action



Promise of GnRH antagonists

Dose dependent reduction of estradiol (E2)

Women with symptoms of uterine fibroids

No estradiol suppression	Target estradiol	Full estradiol suppression
		
Disease Symptoms – Heavy menstrual bleeding/anemia – Abdominal/pelvic pain and pressure	**Outcomes** – Reduction in bleeding – Minimal to no impact on BMD	**Symptoms/Safety Concerns** – BMD loss – Hot flushes
	***ABT not required**	***ABT required for long term use (>6 months)**

*ABT: 1mg estradiol/0.5 mg norethisterone acetate

Obseva

A potential new gold standard treatment for uterine fibroids

Differentiated PK/PD profile

1

Bioavailability > 80%

Reliable absorption

Predictable exposure/effect with each dose

2

Half-life 14-15 hours

Optimal balance for dosing and effectiveness

- Convenient once-daily dosing that fits into women's busy lives
- Blood levels that last long enough to allow flexibility in dosing time

3

No CYP3A4 induction/food effect

"No hassle" administration profile

- Can be taken with or without food
- No relevant interactions with hormonal add-back therapy, oral iron, calcium or other common medications

Uterine fibroids are ruining lives…

No two women are the same, but millions share a common problem: suffering the daily consequences of uterine fibroids



Yselty® 200 mg once daily with concomitant ABT

For long-term use for women for whom ABT is appropriate

Yselty® 100 mg once daily without ABT

For long-term use for women with a contraindication to or who prefer to avoid ABT



Yselty® 200 mg once daily without ABT

For short-term use (up to 6 months) when rapid reduction in fibroid and uterine volume is desired

…Yselty®, designed to treat more women

Obseva

The hypothetical patients represented on this slide are for illustrative purposes only as no strength of linzagolix has been approved nor is there FDA-approved Prescribing Information to guide clinical decisions

Up to 50% of US women suffering from uterine fibroids may have a contraindication to hormonal ABT*

Black women are overrepresented



*US FDA elagolix PI, section 4. Contraindications and section 5.1. Warnings and precautions – thromboembolic disorders and vascular events ** Proportion of individuals with hypertension - Overall population Male vs Female: 47% vs 43% **Hales et al., Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360

Obseva

Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#nation ; https://www.cdc.gov/ 2018

Phase 3 registration studies

PRIMROSE 1 (US) and PRIMROSE 2 (EU/US)



Primary efficacy endpoint: proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline

Patients in the studies received no Vitamin D or calcium supplementation

ABT = Add Back Therapy (1mg estradiol + 0.5 mg norethindrone acetate)

Obseva

PRIMROSE 1 and 2 achieved primary endpoint for both doses

Responder* analysis at week 24



*Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline

Error bars are 95% CI

PRIMROSE 1 and 2 achieved sustained reduction in MBL

Responder* analysis at week 52



*Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline

Significant pain reduction maintained at weeks 52 and 64



Pain assessed on Numerical Rating Scale: 0-10

LGX 200 mg without ABT significantly reduces uterine volume

Substantial reduction compared to placebo & LGX 200 mg with ABT at Week 24



24-week efficacy data support Yselty® (linzagolix) as potential best-in-class GnRH antagonist

Caution advised when comparing across clinical trials. Below data are not head-to-head comparison, and no head-to-head trials have been completed, nor are underway

	Yselty® (Linzagolix)			Elagolix			Relugolix		
	PRIMROSE 1	PRIMROSE 2	Pooled Analysis	ELARIS 1	ELARIS 2	Pooled Analysis	LIBERTY 1	LIBERTY 2	Pooled Analysis
Dose Regimen	200mg + ABT Once daily			300 mg + ABT Twice daily			40mg + ABT Once daily		
Mean Age (y)	41.6	43.1		42.6	42.5		41.3	42.1	
Baseline MBL (mL per cycle)	197	212		238	229		229	247	
Responder* Rate (RR) (%)	75.5	93.9	84.7	68.5	76.5	72.2+	73.4	71.2	72.3++
Amenorrhea	✓	✓		✓	✓		✓	✓	
Pain	✓	✓		NR	NR		✓	✓	
Fibroid Volume	✗	✓		NR**	NR**		✗	✗	
Uterine Volume	✗	✓		NR**	NR**		✓	✓	
Menstrual Blood Loss	✓	✓		✓	✓		✓	✓	
Anemia	✓	✓		✓	✓		✓	✓	
Quality of Life	✓	✓		✓	✓		✓	✓	

Obseva

Source: Company information Note: NR = Not reported.
*Primary endpoint: Proportion of women with menstrual blood loss ≤ 80 mL (by alkaline hematin method) and ≥ 50% reduction from baseline ** P-value not reported
+ Simon et al, Obstet Gynecol 135, 1313-1326 2020 ++ Venturella R et al, ESHRE 2020 abstract.

Minimal BMD change with both doses, plateauing after week 24

Expected age-related BMD decline observed in placebo arm at Week 52



Bone mineral density – no change in z-scores

Expected age-related BMD decline observed in placebo arm at Week 52



Z-score compares BMD to the average values of a person of the same age and gender.
A score < -2 is a sign of less bone mass than expected

Favorable tolerability profile

Summary of adverse events—week 24 to 52

Number (%) of women	PRIMROSE 1			PRIMROSE 2	
	Placebo	Yselty® 100 mg	Yselty® 200 mg + ABT	Yselty® 100 mg	Yselty® 200 mg + ABT
	n=31	n=62	n=70	n=79	n=84
Subject with at least one TEAE	12 (38.7)	25 (40.3)	25 (35.7)	22 (27.8)	21 (25.0)
TEAE leading to discontinuation	1 (3.2)	2 (3.2)	1 (1.4)	7 (8.9)	1 (1.2)
SAE related to linzagolix	0	0	0	0	0
Occurrence after week 24 of most frequently reported AEs (> 5%) up to week 24					
Hot flush	0	1 (1.6)	0	2 (2.5)	3 (3.6)
Headache	1 (3.2)	3 (4.8)	0	1 (1.3)	1 (1.2)
Anemia	1 (3.2)	0	0	2 (2.5)	1 (1.2)

Designed to treat more women

Excellent clinical data driving differentiated profile

Potentially best-in-class

- Unique PD/PK Profile
- Efficacy sustained up to 52 weeks for all dose regimens

Favorable tolerability profile

- No safety signal of concern
- BMD remains within normal ranges during and after treatment

Unique set of treatment options

- Unique low dose option without ABT
- Significant uterine volume reduction for 200 mg without ABT

ABT-containing regimens may be contraindicated in up to 50% of US women with uterine fibroids based on the elagolix US label* and analysis of CDC data**

*US FDA elagolix PI, section 4. Contraindications and section 5.1. Warnings and precautions – thromboembolic disorders and vascular events

** Current Cigarette Smoking Among Adults in the United States. Centers for Disease Control and Prevention https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#nation ; https://www.cdc.gov/2018

Endometriosis

An emotionally and physically painful condition

$22B/yr
total US costs

176 million
women worldwide suffer from endometriosis

60%+
of women feel symptoms by age 16

Quality of Life

premenopausal women may experience pelvic pain, pain during intercourse and defecation, infertility and emotional distress

Endometriosis affects up to

10%+ in the general population

50%+ in the fertile population

60%+ in patients with chronic pelvic pain

5 million
women in the US are treated annually for endometriosis

Obseva

Cardozo et al., Am J Obstet Gynecol 2012; 2017; Stewart et al. NEJM, 2015; Flynn et al., Am J Obstet Gynecol 2006; Truven Health, Fibroid Foundation website

Phase 2b EDELWEISS in endometriosis



Enrollment 328 patients, ~65/arm

50 sites in US (n=177)

14 sites in EU (n= 151)

Primary efficacy endpoint: VRS PAIN SCORE RESPONDER RATE

Secondary endpoint: BMD**

Patients were provided with Vitamin D and calcium

Obseva

* Titration after 12 weeks based on E2 serum level at weeks 4 and 8

**BMD = bone mineral density

Phase 2b EDELWEISS in endometriosis







Potential point of differentiation as 75mg partial suppression dose is nearly as effective as 200mg full suppression dose

*p value <0.05 **p value <0.01 ***p value <0.001 for linzagolix doses compared to placebo

Phase 2b EDELWEISS in endometriosis

Sustained improvement in overall endometriosis symptoms (PGIC)



Phase 2b EDELWEISS in endometriosis

75 mg effective without significantly affecting BMD



Phase 3 endometriosis trial

EDELWEISS 3



Co-Primary efficacy endpoint: DYS/NMPP Responder Analysis

Patients are provided with Vitamin D and calcium

ABT: Add Back Therapy (estradiol + norethindrone acetate)

Prostate cancer

The second most prevalent form of cancer in men and a leading cause of death due to cancer[1]

3.8%

Of all cancer deaths in men in 2018 due to prostate cancer[2]

1.3M

New cases of prostate cancer reported globally in 2018[3]

2X Mortality Rate

In African-American men compared to Caucasians; incidence rate of 158.3 new cases diagnosed per 100K African-American men[4]

~130K

Number of patients in the US treated with Lupron

$600M

Total US sales for GnRH agonists

Lupron was the biggest product in the US with nearly $350M in revenue

$2.1B

Total global prostate cancer market for GnRH agonists in 2020[5]

Or over half of the total global GnRH agonist market[6]

Obseva

[1-4.] World J Oncol. 2019. 10; 63
[5]. IMS MIDAS data, monthly audit Dec 2020
[6]. Evaluate Pharma, aggregation of brokers forecast, 2020

Advanced prostate cancer opportunity

Current Standard of Care	Aims to reduce testosterone (T) to castration levels
Limitations	Injectable GnRH agonists (leuprolide) most commonly used but associated with initial T level spike that can worsen symptoms and delay recovery upon drug discontinuation
Benefit of GnRH antagonists	Evidence from pooled analyses suggest lower cardiovascular risk with GnRH antagonists versus GnRH agonists[1]
Paradigm Change	Once-daily oral drugs that can safely and effectively suppress T levels would represent a paradigm change in chronic treatment of the disease
Superiority of relugolix	Myovant's relugolix (Orgovyx™) demonstrated superiority in Phase 3 versus Lupron and launched in January 2021

Obseva

[1] Albertsen et al., Eur Urol. 2014. 65; 565

GnRH analogues in prostate cancer*

Profile			Efficacy††				Safety		
GnRH analog	Delivery Route	Flare Effect†	Castration on Day 4 (%)	Castration on Day 15 (%)	Sustained T Level to 48 Weeks (%)	PSA Response at Day 15 (%)	MACE‡ Overall/ Prior History (%)	Injection Site Reaction (%)	Hot Flush (%)
GnRH Agonist									
Leuprolide	Injection (Every 1-3 months)	Yes	0	12	89	20	6.2/17.8	14	51.6
Degarelix§	Injection (Monthly)	No	96	99	97	-	-	40	26.0
Relugolix	Oral	No	56	99	97	79	2.9/3.6	n/a	54.3

*Phase 3 relugolix (HERO) results for leuprolide and Relugolix (Shore et al., NEJM. 2020; 382: 2187 -96 ; Degarelix package insert (PI)
†Flare effect = initial spike in T levels upon treatment initiation due to initial activation of GnRH receptor
††Responder = Testosterone levels <50 ng/dL (i.e., castration)
‡MACE=major cardiovascular event after 48 weeks of treatment; KM analysis showed 54% lower risk in relugolix group vs leuprolide group
§Degarelix PI: Day 3 and Day 14; sustained levels to Day 364 for 240/80mg dose; *rate of hot flush for leuprolide in Degarelix studies was 21%

Obseva

ObsEva's linzagolix could potentially challenge the current standard of care as the best-in-class oral GnRH antagonist for advanced prostate cancer

- Potentially best-in-class GnRH antagonist in uterine fibroids & endometriosis
- ObsEva exploring development of linzagolix in combination with estrogen for the treatment of advanced prostate cancer
- Potential improvement on GnRH antagonist-only regimen by further decreasing cardiovascular & bone loss risk, and mitigating hot flushes: Phase 3 results showed similar hot flush rates (>50%) for relugolix and leuprolide[1]
- ObsEva has exclusive global rights (excluding Asia) to linzagolix for all indications

[1] Shore et al., NEJM. 2020; 382:2187-96

Obseva
nature meets nurture

EBOPIPRANT

Potential To Delay Preterm Birth To Improve Newborn Health And Reduce Medical Costs

Preterm birth is delivery before 37 weeks of pregnancy

Life altering & costly

$26B/yr
US economic burden

>1
In 10 babies are born preterm

1 million
preterm related deaths in 2015 WW[1]

LEADING

cause of death
in children
under age 5

Babies surviving early birth face greater likelihood of lifelong disabilities

Preterm birth, a costly burden per baby

$16.9B+ US infant medical costs

$195K+ average cost per US survivor infant born 24-26 weeks

$50K average US cost for a preterm infant

Obseva

WHO 'Born Too Soon: The Global Action Report on Preterm Birth' (2012); Kissin et al. NEJM, 2014
Behrman et al., National Academies Press, 2007
[1]WHO: 15 million babies born preterm each year worldwide, and number is rising.

Ebopiprant is designed to treat preterm labor (PTL)

	Treating Preterm Labor	Preventing Preterm Labor
Drug(s)	No FDA–approved PTL treatment available in US Current treatment in US includes off-label use of non-selective prostaglandin (COX) inhibitors, Indomethacin, calcium channel blocker, beta-mimetics; all are associated with safety issues that limit use Atosiban (oxytocin receptor antagonist) approved in EU/some Asian countries	Makena approved for prevention of PTL in women with history of preterm birth Not approved for treatment of PTL Potential withdrawal from US market after failed confirmatory trial
Use	Use in setting of active preterm labor and threatened premature delivery	Use starts between 16 and 20 weeks of pregnancy

Ebopiprant: an advancement in treatment of preterm labor

Orally active, selective prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$) receptor antagonist



ebopiprant

Selectively blocks the $PGF2_{2\alpha}$ receptor

Potential to treat preterm labor with improved safety over non-selective COX *inhibitors (NSAIDS)

*COX: cyclooxygenase

Ebopiprant is designed to delay delivery by at least 48 hours

Short-term prolongation of pregnancy *(at least 48 hours)* provides a critical window for impact on neonatal outcomes:

- Allows full effect of corticosteroids on neonatal lung maturity
  - Prematurity associated with respiratory complications due to insufficient lung maturation
  - Corticosteroids used to speed up maturation process
  - Maximum effect occurs ~48+ hours after administration
- Allows patient transfer to centers with NICU*

Obseva

*NICU=neonatal intensive care unit

Ebopiprant Phase 2a PROLONG study

Dosing period and FU visit
- Visits at site -

Maternal and neonatal FU
- Site visits or medical records -

Infant follow-up
- Non-interventional, no site visits -



Study design:

- Double-blind, randomized
- Atosiban + Ebopiprant vs
- Atosiban + Placebo

Endpoints:

- Incidence of delivery within 48 hours and 7 days of treatment
- Time to delivery and delivery prior to 37 weeks of gestation
- Maternal, fetal, neonatal safety

Ebopiprant Phase 2a PROLONG study

Demographics and baseline characteristics

	Atosiban + Placebo	Atosiban + Ebopiprant
	n=55	n=58
Mean age – years (SD)	29.6 (5.1)	29.7 (5.7)
Race		
White – n (%)	39 (70.9%)	42 (72.4%)
Asian – n (%)	16 (29.1%)	14 (24.1%)
Mean (SD) gestational age – weeks	29 (3.0)	30.2 (2.6)
24 to 30 weeks – n (%)	23 (41.8%)	25 (43.1%)
30 to 34 weeks – n (%)	32 (58.2%)	33 (56.9%)
Singleton – n (%)	41 (74.5%)	42 (72.4%)
Twin – n (%)	14 (25.5%)	16 (27.6%)

Overall delivery rate within 48 hours reduced by >40%

Percentage of women delivering within 48 hours



OR (90% CI)	0.52 (0.22, 1.23)	1.05 (0.20, 5.43)	0.77 (0.21, 2.89)	0.39 (0.15, 1.04)	2.05 (0.23, 18.1)

Obseva

Singleton delivery rate within 48 hours reduced by >50%

Percentage of women delivering within 48 hours



OR (90% CI)	0.39 (0.15, 1.04)	0.34 (0.08, 1.49)	0.44 (0.12, 1.62)

Reduced Singleton 24- to 30-week delivery rate within 7 days

Percentage of women delivering within 7 days



OR (90% CI)	0.81 (0.36, 1.83)	0.53 (0.14, 2.01)	1.09 (0.37, 3.18)

Obseva

Ebopiprant Maternal and neonatal safety

	Atosiban + Placebo	Atosiban + Ebopiprant
Maternal & Fetal AEs until 7 days post treatment – n (%)	n=55	n=58
At least one TEAE	23 (41.8%)	24 (41.4%)
SAEs	0	0
Most common (constipation)	4 (7.3%)	4 (6.9%)
Neonatal AEs and prematurity related Events – n (%)	n=69	n=72
At least one TEAE or prematurity related event	41 (59.4%)	44 (61.1%)
SAEs	9 (13.0%)	10 (13.9%)
Most common (neonatal jaundice)	28 (40.6%)	22 (30.6%)
Neonatal outcomes – n (%) singletons	n=41	n=40
Duration of hospitalization in days – mean (SD)	18.0 (25.8)	13.7 (16.5)

Ebopiprant Phase 2b dose ranging study Anticipated initiation Q4:21*

Study Design:

- Global (EU and Asia)
- Dose escalating
- Double-blind, randomized
- Atosiban + Ebopiprant
- Atosiban + Placebo

Key Eligibility Criteria:

- Single gestation
- 24-34 weeks
- Confirmed preterm labor
- No contraindication to tocolysis

Endpoints:

- Optimal dose
- Incidence of delivery within 48 hours and 7 days of treatment
- Time to delivery and delivery prior to 37 weeks of gestation
- Maternal, fetal, neonatal safety

Obseva

*Discussions with FDA on requirements for US clinical development to occur in parallel

Ebopiprant development in the US

- FDA approved the beta-mimetic ritodrine (Yutopar) in 1980
  - Withdrawn from the market in 1995 due to cardiovascular complications
  - No subsequent US approvals for PTL treatment
- Discussions with FDA regarding clinical development program will be required
- Currently engaging with US KOLs/advocacy groups
- Potential approaches include:
  - Combination with non-registered standard of care
  - Comparison with non-registered standard of care
  - Open label single-arm study vs historical data
- Single Phase 3 study may be acceptable

Ebopiprant, a potential breakthrough for preterm labor

Over 50% reduction of singleton delivery within 48 hrs

Enabling administration of critical drugs for neonatal protection

Favorable maternal, fetal and neonatal safety

Maternal, fetal and neonatal safety comparable to placebo

Supports advancing ebopiprant into Phase 2b

Phase 2b study will include higher doses to more fully define ebopiprant potential and the longer-term benefits for babies

Ebopiprant has demonstrated proof of concept in delaying preterm birth

Investor highlights

1. Pursuing large indications for conditions that compromise **women's reproductive health and beyond**
2. Yselty® has potential **best in class efficacy, favorable tolerability, and unique flexible dosing options**
3. Ebopiprant is the only known product in development for preterm labor and has **positive Phase 2a data**
4. Business model built on strong **global partnerships and collaborations**
5. Seasoned **leadership team** with a track record for success

Thank you

Obseva